Coherus Biosciences's total assets for Q3 2025 were $516.52M, an increase of 17.53% from the previous quarter. CHRS total liabilities were $428.75M for the fiscal quarter, a 34.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.